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Abstract: DCIS is a heterogeneous group of non-invasive cancers of the breast characterized by various degrees of dif-
ferentiation and unpredictable propensity for transformation into invasive carcinoma. We examined the expression and 
prognostic value of 9 biological markers with a potential role in tumor progression in 133 patients with pure DCIS treated 
with breast conserving surgery alone, between 1982–2000. Histology was reviewed and immunohistochemical staining was 
performed. Pearson correlation coefﬁ  cient was used to determine the associations between markers and histopathological 
features. Univariate and multivariate analysis examined associations between time to recurrence and clinico-pathologic 
features and biological markers.
Median age at diagnosis was 55 years (25–85). With a median follow up of 8.91 years, 41/133 patients recurred (21 as 
invasive recurrence). In this cohort 13.5% had low, 43% intermediate and 42% high nuclear grade. Comedo necrosis was 
found in 65% of cases. Expression of ER (62.4%), PR (55.6%), HER2/neu (31.6%), MIB1 (39.8%), p53 (22.6%), p21 
(39.8%), Cyclin D1 (95.5%) calgranulin (20.5%), psoriasin (12%), was found in DCIS. HER2/neu was overexpressed in 
45% that recurred as DCIS and 42.9% that recurred as invasive cancer, and only in 26.1% in cases that never recurred. On 
univariate analysis, HER2/neu overexpression was the only marker associated with an increased risk for any recurrence 
(p = 0.044). The hazard ratio for recurrence for HER2/neu positive DCIS was 1.927 (conﬁ  dence interval 1.016–3.653) 
compared to HER2 negative DCIS. On multivariate analysis, HER2/neu overexpression remained the only independent 
variable signiﬁ  cantly associated with any recurrence (p = 0.014) and with invasive recurrence (p = 0.044).
This data suggest that HER2/neu testing may become an important parameter in the management of DCIS and the treatment 
of cases with positive HER2/neu status could be modiﬁ  ed accordingly, similar to the current approach for HER2/neu posi-
tive invasive disease.
Keywords: breast cancer, ductal carcinoma in situ, molecular markers, biological markers, HER2/neu, tumour invasion, 
prognosis, recurrence
Introduction
With the adoption of screening mammography, the incidence of ductal carcinoma in situ (DCIS) has risen 
dramatically(1). DCIS is a heterogeneous group of pre-invasive cancers of the breast characterized by 
various degrees of differentiation and propensity for transformation into invasive carcinoma. Approximately 
16–22% of DCIS treated with breast conserving surgery (BCS) alone will develop recurrence. Approxi-
mately half of them recur in the form of invasive disease which is associated with signiﬁ  cantly reduced 
overall survival; whereas, the other half recur as DCIS(2). Postoperative radiotherapy reduces the recur-
rence rate to 7–9%(3–5), of which about half are invasive (4;6). In a large series with 15 years follow up, 
the ﬁ  rst local failure rate was 16%, 2/3 as an invasive cancer, even with adjuvant radiotherapy (7). Cur-
rently our ability to identify this subset of patients that are at risk for developing invasive cancer is limited. 
Therefore, the standard of care for all patients diagnosed with DCIS is BCS followed by adjuvant radia-
tion therapy. Clinical and histologic characteristics that may predict risk of local recurrence in women 
with DCIS have been identiﬁ  ed in several studies (8–11). These include the presence of comedo necrosis, 
architectural subtype, tumor size and width of resection margins (11–21). However, the light microscopic 
examination in DCIS does not accurately identify patients at high risk for recurrence as invasive cancer. 
In recent years, there have been efforts to examine the value of different biological markers as prognostic 8
Nofech-Mozes et al
Clinical Medicine: Oncology 2008:2
and predictive factors in DCIS. Most of the 
molecular changes that characterize invasive breast 
cancer are already present in DCIS, though the 
lesion has not assumed a fully malignant phenotype 
(10;22–25). Previous studies found that the expres-
sion of the estrogen receptor (ER), progesterone 
receptor (PR), HER2/neu, Ki67 a proliferation 
marker, P53, and Bcl-2 correlate with tumor grade 
and are interrelated, but nevertheless do not add 
predictive or prognostic information (26–28). 
Experimental markers that contribute to various 
mechanisms leading to the complex pathway of 
tumor progression have been proposed. These 
include: 1) markers of tumor proliferation and cell 
cycle regulation (mitosin, telomerase, Cyclin D1, 
p21, IGFBP-rP1), 2) intercellular interaction (P 
cadherin, calgranulin, psoriasin), 3) extracellular 
matrix regulation (urokinase plasminogen activator 
system, metalloproteinase and its inhibitors) and 4) 
angiogenesis.
We identiﬁ  ed the need for a study based on a 
large number of cases of pure DCIS who underwent 
uniform treatment and had long follow up. Based 
on our recent review of the literature (29), we 
conducted a study that focused on prognostic mark-
ers with an emphasis on invasive recurrence. A 
panel of markers with a potential role in tumor 
progression that could be evaluated by immuno-
histochemical methods was selected. These include 
estrogen and progesterone receptors, HER2/neu 
overexpression; proliferation marker: MIB1; mol-
ecules involved in cell cycle regulation: cyclin D1, 
p21, p53; and two calcium binding proteins: cal-
granulin and psoriasin.
The aim of this study was to identify novel 
pathological predictors of invasive recurrence to 
enable targeting an effective treatment to those at 
risk. Unnecessary treatment for most women with 
DCIS who will never develop invasive disease 
could be minimized.
Materials and Methods
Cohort 
The study population comprised of 254 patients 
referred for surgical management of pure DCIS to 
one cancer centre between 1982 and 2000. We 
excluded 100/254 patients that were managed by 
mastectomy and those who received adjuvant 
radiation, as these treatments are known to reduce 
the recurrence rate significantly. In 133/154 
patients with BCS and negative margins, we 
reviewed the original pathology and selected 
blocks containing representative tumor.
Demographic, treatment and outcome details 
were extracted from patient charts. The endpoint 
in this study was the development of recurrence, 
whether it was invasive or in situ carcinoma, at 
least six months after the BCS. All ipsilateral in 
situ or invasive carcinoma of ductal origin that was 
diagnosed after the surgical treatment including 
re-excision or completion mastectomies for posi-
tive margins were completed. Any event prior to 
that was attributed to incomplete excision.
Pathology review
A complete pathology review was undertaken by 
one pathologist (SNM). A second pathologist (WH) 
reviewed 20% of the cases to assure at least 90% 
agreement as per the predeﬁ  ned protocol. In cases 
with grossly identiﬁ  ed mass, the entire lesion was 
submitted, while in cases with no gross disease, 
the sectioned specimen was radiographed and areas 
of calciﬁ  cation or architectural distortion were 
sampled. The mean number of blocks per case was 
15. Nuclear grade was determined using the Hol-
land classiﬁ  cation(30). In lesions with mixed pat-
terns, we classiﬁ  ed the lesion based on the higher 
grade. Histological subtype, presence of comedo 
necrosis, presence of invasion, the margin’s status 
and size were also documented. Comedo necrosis 
was considered present for any architectural pattern 
of DCIS in which a central zone of necrotic debris 
with karyorrhexis was identiﬁ  ed. Tumors were 
divided into 2 groups by the presence or absence 
of any amount of comedo necrosis. Margins were 
called positive when DCIS was present on the 
inked or cauterized edge of the specimen. As per 
our cohort deﬁ  nition, cases with positive margins 
were excluded. As a result of the retrospective 
nature of this study, the size of the lesion could be 
accurately deﬁ  ned only in 81 specimens.
Immunohistochemistry (IHC)
A panel of 9 antibodies against: estrogen receptors, 
progesterone receptors, HER2/neu oncoprotein, 
MIB1, cyclin D1, p21, p53, calgranulin, psoriasin; 
was used for immunohistochemistry on formalin 
ﬁ  xed parafﬁ  n embedded tissue sections, following 
the manufacturer’s instructions (Table 1). A posi-
tive and negative control for each antibody was 
included in every run. The positive control for 9
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invasive recurrences. In 36/41 cases, blocks with 
representative recurrent tumors were available, 
these were stained for ER, PR and HER2/neu.
One pathologist (SNM) evaluated all 
immunostains results. Another pathologist (WH) 
reviewed 20% of the stains, including all equivocal 
HER2/neu, and the agreement level was greater than 
90%. Both the retrospective pathology case review 
and the IHC evaluation were undertaken by the 
evaluator who was unaware of the results of the 
other IHC stains and of the patient’s outcome.
Statistical Methods
The data was collected in an Access database. For 
comparison of proportions between the groups, the 
chi-square test was used and differences between 2 
means were assessed with Student t-test for unpaired 
data. Statistically significant differences were 
assumed when p   0.05. SPSS for Windows version 
12 (SPSS Inc.) was used for statistical calculations. 
The Pearson correlation coefﬁ  cient was used to 
determine associations between markers and histo-
pathological features. Univariate survival analysis 
examined associations between time to recurrence 
such as in situ and/or invasive carcinoma and demo-
graphic (age) or pathologic (nuclear grade, comedo 
necrosis) features as well as expression of biological 
markers. Multivariate survival analysis with the Cox 
proportional hazards model was used to identify 
independent variables associated with recurrence.
psoriasin and calgranulin consisted of 2 cases of 
DCIS with an invasive component that were 
included in a previous study. In these cases, 
positive psoriasin and calgranulin immunostains 
correlated with their gene upregulation as shown 
using DNA microarray technique(31). Nuclear 
staining was scored for ER, PR, MIB1, p53, p21, 
cyclin D1 and membranous staining for HER2/neu 
oncoprotein, and both nuclear and cytoplasmic 
staining were scored for calgranulin and psoriasin. 
HER2/neu immunostain was scored from 0 to 3+ 
as per the HerceptTest
TM scoring method. In 
equivocal cases, HER2/neu gene ampliﬁ  cation was 
determined by chromogenic in situ hybridization 
(CISH). This was performed using the Zymed 
SPoT-Light
® HER2 CISH
TM Polymer Detection 
kit (84-0146). HER2/neu gene ampliﬁ  cation was 
determined when there were six or more signals 
per nucleus or when clusters were identiﬁ  ed in the 
tumor cells’ nuclei. The results of all the other 
immunohistochemical markers were recorded as 
continuous variables based on the proportion of 
positive tumor cells (0%–100%) regardless of their 
staining intensity. All the involved ducts on the 
slides were scored. For ER and PR a 10% cut-off 
value for positivity was used to categorize cases 
into positive or negative.
We compared the morphology and the expres-
sion of ER, PR, HER2/neu oncoprotein in the 
primary DCIS and subsequent recurrent tumor in 
the same patients, whether those were in situ or 
Table 1. Antibodies used in the study.
Antibody Clone Manufacture  Cat.  #  Dilution  Host  Antigen
          retrieval
ER 6F11  NovaCastra  NCL-L-PGR-312  1:50  Mouse  (monoclonal)  HIER
          Citrate,  pH6
PR 312  NovaCastra  NCL-ER-6F11  1:100  Mouse  (monoclonal)  HIER
          Citrate,  pH6
HER2 CB11  NovaCastra  NCL-L-CB11  1:400  Mouse  (monoclonal)  HIER
          Citrate,  pH6
MIB1 SP6  LabVision  RM-1906 1:400  Rabbit  (monoclonal)  HIER
          Citrate,  pH6
Cyclin D1  SP4  Biocare  CP236C  1:100  Rabbit (monoclonal)  HIER
          Borg,  pH9.5
p21 EA10  Oncogene  OP64  1:100  Mouse  (monoclonal)  HIER
          Citrate,  pH6
p53 DO7  NovaCastra  NCLP53DO7  1:500  Mouse  (monoclonal)  HIER
          Citrate,  pH6
Psoriasin 47C1068  Imgenex  IMG-409A  1:500  Mouse  (monoclonal)  HIER
          Citrate,  pH6
Calgranulin B  H-90  Santa Cruz  SC-20173  1:200  Rabbit (polyclonal)  HIER
          Citrate,  pH610
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Ethics approval for this study was obtained from 
the Research Ethics Board of the Toronto Academic 
Health Sciences Council.
Results
The median age at diagnosis was 55 years (range 
25–85). There was no significant correlation 
between age and outcome. The median follow up 
period was 8.9 years. During the follow up period 
41/133 patients (30.8%) had a histologically docu-
mented recurrence, 20 (15%) cases as DCIS and 21 
(15.8%) cases as invasive carcinoma. The median 
time to recurrence was 2.7 years, and 5.6 years for 
DCIS and invasive recurrence respectively.
In this cohort, 13.5% were classiﬁ  ed as low 
grade, 43.6% intermediate and 42.9% high nuclear 
grade. Comedo necrosis was found in 65% of cases 
and unequivocal microinvasion was found in 3% 
of cases.
There were no signiﬁ  cant associations found 
between recurrence rate (analyzed for any type of 
recurrence or speciﬁ  cally for invasive recurrence) 
and nuclear grade or comedo necrosis (Table 2).
The distribution of percentage of positive cells 
for the biological markers as demonstrated by 
immunohistochemistry is shown in Figure 1A-H. 
When a cut-off for positivity was deﬁ  ned at  10%, 
the proportion of DCIS showing positive staining 
for the different tumor markers were as follows: ER 
(62.4%), PR (55.6%), HER2/neu (31.6%), MIB1 
(39.8%), p53 (22.6%), p21 (39.8%), Cyclin D1 
(95.5%) calgranulin (20.5%), psoriasin (12%). 
Representative cases of positive immunostains are 
shown in Figure 2(A-F). In 20 cases in which HER2/
neu immunostain was equivocal, HER2/neu gene 
ampliﬁ  cation was tested by CISH to determine its 
status, and 4 cases showed HER2/neu gene 
ampliﬁ  cation. HER2/neu oncoprotein overexpression 
or gene ampliﬁ  cation was positive in 45% and 42.9% 
in cases that recurred as DCIS or invasive cancer 
respectively, but only in 26.1% of cases that never 
recurred (p = 0.04). The difference in ER and PR 
expression between cases that recurred to those 
that did not recur was not statistically signiﬁ  cant 
(Fig. 3). The correlations between the various 
immunostains, tumor grade and comedo necrosis 
are summarized in Table 3. Correlation analysis 
revealed significant associations between ER-
negativity, HER2/neu overexpression, MIB1, p53, 
p21, calgranulin and psoriasin positivity and high 
tumor grade (p   0.01). Comedo necrosis correlated 
with PR-negativity, HER2/neu overexpression, 
MIB1 positivity and p53 positivity (p   0.01). None 
of the markers correlated with microinvasion.
Table 2. Clinical and pathological characteristics and recurrence.
  No recurrence  DCIS recurrence  Invasive recurrence
 N  = 92 N  = 20 N  = 21
Age 57.5  56.6  52
Mean follow up   8.3  10.1  10.4
(years)
Nuclear Grade    
1 n = 18  12 (66.7%)  3 (16.7%)  3 (16.7%)
2 n = 58  44 (75.9%)  5 (8.8%)  9 (15.5%)
3 n = 57  36 (63.2%)  12 (21.1%)  9 (15.8%)
Comedo Necrosis    
Absent n = 45  32 (71.7%)  4 (8.9%)  9 (20.0%)
Present n = 87  59 (67.8%)  16 (18.4%)  12 (13.8%)
Margin    
 1 mm  37 (40.2%)  8 (40%)  9 (42.8%)
1–10 mm  45 (48.9%)  12 (60%)  10 (47.6%) 
 10 mm  7 (7.6%)  0  1 (4.8%)
N/A  3 (3.3%)  0  1 (4.8%)
Mean Tumor Size      
(mm) 10.4  ± 5.32  10.6 ± 3.04 8.92  ± 4.56
N/A  23 (25%)  5 (25%)  6 (28%)
ER Positive  61 (66%)  13 (65%)  12 (57%)
PR Positive  53 (58%)  11(55%)  13 (62%)
HER2/neu   24 (26%)  9 (45%)  9 (43%)
Overexpressed11
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Figure 1. The distribution of positive DCIS cases according to the percentage of positive cells for each of the biological markers.12
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The expression of p21 did not correlate with ER, PR 
or HER2 status. Calgranulin B and psoriasin 
immunostains showed marked intratumoral 
heterogeneity. Most cases showed both positive and 
negative foci of DCIS (Figs. 2E and 2F). Interestingly, 
Figure 2. 2A- Positive membranous immunostain for HER2/neu oncoprotein in high grade DCIS (clone: CB11, X200) 2B- Positive nuclear 
immunostain for p21in 50% of the cells in intermediate grade DCIS. Note the variable intensity of stains. (x100) 2C- Positive nuclear immu-
nostain for MIB1 in 30% of the cells in high grade DCIS. (x100) 2D- Positive nuclear immunostain for cyclin D1 in 100% of the cells in low 
grade, cribriform DCIS. (x50) 2E- Positive nuclear and/or cytoplasmic immunostain for psoriasin (S100A7). The staining is heterogeneous, 
with negative and positive areas of DCIS. (x50) 2F- Positive nuclear and/or cytoplasmic immunostain for calgranulin (S100A9). The staining 
is heterogeneous with some negative and some strongly positive cells within the same focus of DCIS. Note the positive reaction in the 
granulocytes (arrow, x200).
the same foci of DCIS that were positive for psoriasin 
were also positive for calgranulin, while other foci 
of DCIS in the same case were negative for both. 
Calgranulin B and psoriasin expression were highly 
associated (Pearson coefﬁ  cient 0.679, p < 0.01); 13
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Figure 3. The proportion of Her2/neu overexpressed cases was signiﬁ  cantly higher in patients with invasive or in situ recurrence compared 
with those that never recurred. The difference in ER and PR expression was not signiﬁ  cant.
(17/20). The nuclear grade of the 2 discordant 
recurrent tumors was higher than the primaries. 
The expression proﬁ  le of ER/PR HER2/neu was 
identical in 58.8% (10/17). ER status changed in 
2 cases (1 gain and 1 loss). PR status changed in 
4 cases (1 gain and 3 losses). Two cases showed 
loss of HER2/neu overexpression and a third case 
showed a gain. This third case showed a minor 
low-grade component featuring similar expression 
of markers to the primary, and a major high-grade 
component associated with loss of PR, and gain of 
HER2/neu overexpression.
Comparison between primary DCIS and inva-
sive recurrence (n = 21; blocks were available in 
19 cases): The nuclear grade was concordant in 
57% (12/21). Of the 9 discordant cases 7 showed 
a higher nuclear grade in the recurrence. The 
expression profile of ER/PR HER2/neu was 
identical in 57.8% (11/19). ER status changed in 
4 cases (3 gains and one loss). One case showed 
loss of PR. In 4 cases there was loss and in one 
case a gain of HER2/neu overexpression. In one 
case the loss of HER2/neu overexpression was 
coupled by gain of PR.
calgranulin B expression was inversely associated 
with ER and PR expression and directly associated 
with HER2/neu status. Psoriasin expression showed 
strong association with high nuclear grade and an 
inverse association with ER status. Of the 41 patients 
that recurred, only 4 initial tumors were positive for 
psoriasin, and all recurrences were non-invasive. In 
2 of these cases, HER2/neu was overexpressed. This 
difference between psoriasin-positive and psoriasin-
negative DCIS only approached significance 
(p = 0.065). On univariate analysis, HER2/neu 
overexpression was the only marker associated with 
a higher risk for any recurrence (p = 0.044). The 
hazard ratio for recurrence for HER2 positive DCIS 
is 1.927 (conﬁ  dence interval 1.016–3.653) compared 
to HER2 negative DCIS. On multivariate analysis 
HER2/neu overexpression remained the only 
independent variable signiﬁ  cantly associated with 
any recurrence (p = 0.014) and with invasive 
recurrence (p = 0.044).
Comparison between primary DCIS and in situ 
recurrence (n = 20; blocks were available 
in 17 cases): The nuclear grade was concordant in 
90% (18/20), and comedo type necrosis in 85% 14
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Discussion
In the current study, we analyzed histological char-
acteristics and a panel of 9 antibodies in a well 
characterized group of 133 cases of pure DCIS 
treated in a single cancer center by BCS alone with 
a long follow up. We performed the immunohisto-
chemical staining on an individual slide rather than 
using tissue microarray technique to assure optimal 
representation of small lesions and to evaluate intra-
tumoral heterogeneity. The study has generated a 
number of observations related to the prognosis of 
DCIS. None of the morphological parameters includ-
ing nuclear grade and the presence of comedo necro-
sis were associated with recurrence in our study. 
Earlier studies have reported contradicting results 
with regards to histological features as predictors of 
recurrence in DCIS. Both the NSABP B-17(6) and 
EORTC(10) trials, observed a signiﬁ  cant association 
between comedonecrosis and local failure. The role 
of margin status as an independent risk factor for 
recurrence continues to be controversial. A recent 
multivariate analysis(32) of 445 cases of DCIS 
treated by excision alone showed that margin width 
was the most signiﬁ  cant predictor of local recurrence. 
The 8 years follow up report on the NSABP B-17 
and the 10.5 years follow up report on the NSABP 
B-24 trials failed to demonstrate that involved mar-
gin is a signiﬁ  cant predictor of recurrence(20;33). 
Nuclear grade but not comedo necrosis was also a 
signiﬁ  cant predictor of local recurrence. In an Aus-
tralian nested case-control study(8), both nuclear 
grade and extensive necrosis were signiﬁ  cant predic-
tors of recurrence. The Australian study included 
patients managed by BCS or mastectomy with or 
without adjuvant radiotherapy or hormonal therapy.
In the current study, we have demonstrated for 
the ﬁ  rst time, that HER2/neu is a signiﬁ  cant factor 
that predicts for invasive recurrence independent of 
tumor grade. In 1988, van de Vijver et al. described 
overexpression and ampliﬁ  cation of HER-2/neu in 
carcinoma-in-situ; but did not correlate it with prog-
nosis in his study(34). We found that HER2/neu was 
positive in 31.6% of the cases. This is concordant 
with recent studies that demonstrated HER2/neu 
expression in 32% (n = 95) and 33% (n = 151) of 
DCIS(26;35;36). Earlier studies reported a higher 
level of HER2/neu overexpression in 55% of DCIS 
in general(27;28;37), and in 60%–70% in high grade 
DCIS(10;38). The higher percentage of positive 
HER2/neu cases reported earlier could be related to 
the use of non-standarized methodology or different 
scoring methodology. We have demonstrated 
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a signiﬁ  cant association between HER2/neu over-
expression in DCIS and any recurrence and more 
notably, we have demonstrated a signiﬁ  cant asso-
ciation speciﬁ  cally with recurrence as an invasive 
cancer. HER2/neu overexpression remained a sig-
niﬁ  cant predictive factor even when morphologic 
and other biologic markers investigated in this study 
were accounted for in multivariate analysis. Our 
ﬁ  ndings are in line with one case-control study(35) 
that found a signiﬁ  cant association between HER2/
neu positivity and increased risk for recurrence. 
However, in that case-control study, the prognostic 
value of biological markers was examined in DCIS 
patients that were treated with various modalities 
and did not analyze their data speciﬁ  cally for inva-
sive type of recurrence. They found that HER2/neu 
was positive in 41% of DCIS that recurred and in 
12% in DCIS that did not recur. The difference in 
HER2/neu status was signiﬁ  cant even when adjusted 
for high grade (p = 0.01). Other studies showed that 
HER2/neu positivity correlated with high tumor 
grade and comedo necrosis, p53 accumulation, and 
was inversely related to ER, PR and bcl-2 expres-
sion, but was not found to be an independent prog-
nostic factor(28;37;39;40). Stark et al. found an 
association between HER2/neu expression in benign 
breast lesions and an increased risk of subsequent 
development of invasive carcinoma. They con-
ducted a case-control study that examined HER2/
neu status in biopsies of benign breast disease 
including non-proliferative and proliferative lesions, 
atypical ductal hyperplasia and DCIS with a mean 
follow up of 10.2 years. Gene ampliﬁ  cation was 
detected in 9.5% of the benign specimens and was 
associated with increased risk of invasive breast 
cancer. Nevertheless, this association only 
approached statistical signiﬁ  cance. Presently, it is 
unclear what is the role of HER2/neu overexpression 
in the pathway of tumor progression. The HER2/neu 
gene encodes a member of the epidermal growth 
factor (EGF) receptor family of receptor tyrosine 
kinases. This receptor has no known ligand binding 
domain of its own and therefore cannot bind growth 
factors. However, it does bind tightly to other ligand-
bound EGF receptor family members to form homo 
or heterodimer, stabilizing ligand binding and 
enhancing kinase-mediated activation of down-
stream signaling pathways, such as those involving 
mitogen-activated protein kinase and phosphati-
dylinositol-3 kinase. It has been suggested that 
HER2/neu signaling mediates cell motility(41;42). 
This is supported by studies that examined 
HER2/neu expression in mammary Paget’s dis-
ease(43). It is plausible that the overexpression of 
HER2/neu in DCIS contributes to cell migration 
that may play a role in the transition from DCIS to 
invasive cancer. Based on the observation that the 
overall incidence of HER2/neu gene ampliﬁ  cation/
protein overexpression in invasive carcinoma is 
lower in invasive carcinoma than in DCIS, other 
investigators suggested that other molecular events 
might be more critical in the progression from in 
situ to invasive cancer(36).
S100 Proteins are a group of calcium binding 
proteins. Their exact biological function is yet to be 
clariﬁ  ed(44;45). S100A7 protein also known as pso-
riasin, has been shown to be associated with poor 
survival in invasive breast cancer(46). We found that 
psoriasin was expressed only in 12.5% of DCIS. 
Psoriasin positive cases did not develop an invasive 
recurrence, even when the tumors were high grade, 
HER2/neu positive or exhibit comedo necrosis, a 
feature that has been thought to be associated with 
increased risk of recurrence. This observation should 
be addressed cautiously since the number of psoriasin 
positive cases in our study is low. Previous studies 
found that psoriasin level was higher in DCIS with 
invasive carcinoma and demonstrated a high psoria-
sin expression in DCIS with comedo necrosis(47).
In the present study, calgranulin B (S100A9) 
another member of the S100 family of proteins, 
was signiﬁ  cantly associated with high nuclear 
grade, psoriasin positivity and HER2/neu overex-
pression and was inversely associated with ER and 
PR. Calgranulin B did not predict for invasive or 
DCIS recurrence in our study. The association of 
calgranulin expression and high tumor grade is in 
line with a previous study that included only 25 
cases of DCIS.
Cyclin D1 was expressed almost uniformly in 
DCIS usually with high proportion of positive 
tumor cells and did not correlate with prognosis in 
our study. In earlier studies, Cyclin D1 expression 
was associated with tumor grade(25), and inversely 
associated with local recurrence and shorter time 
to recurrence(48).
Our study showed that 39.8% of DCIS had more 
than 10% of the cells positive for p21, which is 
close to the level of expression reported earlier(35). 
In our study p21 expression did not correlate with 
patient outcome, or with the other markers. The 
correlation between p21 and tumor grade was sig-
niﬁ  cant at a level of p = 0.05 which was weaker 
than some of the other markers. There are conﬂ  icting 16
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reports regarding the association between p21 and 
both nuclear grade and ER status in DCIS(49). In 
only one previous study, p21 was shown to be a 
signiﬁ  cant predictor for recurrence independent of 
the ER/PR/HER2/neu status of the tumor(35). Other 
studies did not conﬁ  rm that p21 expression was 
related to recurrence of DCIS(26;50) and it was not 
correlated to any other biological marker(26).
In the current study, there was no signiﬁ  cant 
association between ER, PR, MIB1 and P53 
expression and recurrence. These results are in 
accordance with other studies that examined these 
markers in DCIS treated exclusively by local exci-
sion(26;28;40).
When recurrent tumors were compared with their 
paired primaries, there was a high level of concordance 
in nuclear grade and comedo necrosis in most tumors 
that recurred as DCIS; whereas, there was a signiﬁ  cant 
difference in nuclear grade in cases with invasive 
recurrence (p = 0.018). In both types of recurrences, 
the discordant cases showed a tendency for recurrent 
tumors to be of a higher nuclear grade than the prima-
ries. A high level of concordance was maintained 
when each marker was assessed individually; how-
ever, the concordance of the panel of biological mark-
ers was noted only in about 60% of the cases. Gain or 
loss of expression of molecular markers occurred not 
only in tumors recurring as invasive carcinoma, but 
also in cases that maintained their in situ histology. 
These ﬁ  ndings are without the impact of radiation or 
systemic therapy. Our ﬁ  ndings suggest that the bio-
logical proﬁ  le should be evaluated on recurrent tumors 
since they may inﬂ  uence the patient’s treatment(51).
Our study suggests that biological markers as 
HER2/neu and possibly psoriasin add signiﬁ  cant 
information to the prognosis of DCIS over the cur-
rently accepted Van Nuys prognostic index. The 
results might indicate that HER2/neu testing should 
be considered in DCIS at the time of diagnosis. Con-
ﬁ  rmation of these results may initiate a change in the 
current standard of care for DCIS and speciﬁ  cally to 
manage patients at an increased risk of recurrence 
more aggressively. Furthermore, treatment of selected 
high risk cases with humanized monoclonal antibod-
ies directed against HER2/neu oncoprotein may be 
considered, and is currently under clinical trial in the 
neoadjuvant setting(52).
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